Background Bone is the most common site of metastatic disease associated with breast
cancer (BC). Bisphosphonates inhibit osteoclast‐mediated bone resorption, and novel …

Background Bone is the most common site of metastatic disease associated with breast
cancer (BC). Bisphosphonates inhibit osteoclast‐mediated bone resorption. Objectives To …

Patient-reported outcomes (PROs) can be included in clinical trials as primary or secondary
endpoints and are increasingly recognized by regulators, clinicians, and patients as …

Background Enzalutamide, an androgen-receptor inhibitor, has been associated with
improved overall survival in men with castration-resistant prostate cancer. It is not known …

PURPOSE To investigate the benefit of chemotherapy in patients with symptomatic hormone-
resistant prostate cancer using relevant end points of palliation in a randomized controlled …

Summary Background Lutetium-177 [177 Lu] Lu-PSMA-617 is a radiolabelled small
molecule that delivers β radiation to cells expressing prostate-specific membrane antigen …

Capecitabine, Bevacizumab, and Mitomycin in First-Line Treatment of Metastatic Colorectal
Cancer: Results of the Australasian Ga Page 1 Capecitabine, Bevacizumab, and Mitomycin in …

Background Previously, results from the TheraP trial showed that treatment with lutetium-177
[177 Lu] Lu-PSMA-617 improved frequency of prostate-specific antigen (PSA) response rate …

This review concluded that there were significant benefits in overall survival and progression-
free survival with longer duration regimens of chemotherapy compared with shorter duration …

This well-conducted review concluded that extension of chemotherapy, particularly with a
third-generation regimen, substantially improved progression-free survival and had a lesser …